Federal prosecutors had enough evidence to prove felony violations against Alibaba for letting dangerous drugs, chemicals, and pill presses flow to American consumers for eight years. They pushed for a deferred prosecution agreement with a full felony admission. What they got instead was a $600 million check, a misdemeanor acknowledgment, and a Justice Department spokesperson calling it a victory with a straight face.
Eight Years of Dangerous Junk Sold to Americans, Zero Felonies
According to CBS News, Alibaba and its U.S. payment processor AUS Merchant Services spent the better part of a decade failing to stop the sale of counterfeit drugs, hazardous chemicals, and pill presses to American customers. This wasn't a mystery to anyone inside the company. Employees raised compliance concerns internally. The warnings got ignored. The sales kept coming.
The investigation started during Trump's first term and only gathered steam from there. CBS News reports that a senior official in then-Deputy Attorney General Lisa Monaco's office actually pushed prosecutors to keep digging rather than settle cheap. They dug. The evidence got stronger. Career prosecutors concluded they had what they needed to prove felony violations of the Food, Drug and Cosmetic Act, a law that has been on the books since 1938 specifically to stop exactly this kind of conduct.
So what happened when the case finally came to a head? Justice Department leadership stepped in and made it disappear. Not disappear disappear. Six hundred million dollars in penalties and forfeitures is not nothing. But instead of a deferred prosecution agreement with a felony admission, the companies got a non-prosecution agreement admitting only to misdemeanor violations. One person familiar with the evidence told CBS News the result was "beyond disappointing" and that a non-prosecution agreement "is not even a slap on the wrist."
The DOJ's Defense Is Actually Worse Than Saying Nothing
Asked by CBS News to explain itself, the Justice Department did not disappoint in the wrong direction. "This Department of Justice does not believe in regulation by prosecution," a department spokesperson said. Read that sentence again. The Justice Department does not believe in prosecution.
The spokesperson also said ensuring food safety is "a top priority for the Trump administration." This claim was made in the same statement explaining why they declined to prosecute a Chinese company that sold dangerous drugs to Americans for eight years after its own employees sounded the alarm. The cognitive dissonance involved is genuinely staggering.
Lisa Gilbert, co-president of consumer advocacy nonprofit Public Citizen, did not mince words. "President Trump always talks of being tough on crime, but his administration guts enforcement for corporate law-breakers," she told CBS News. When Americans' health is on the line, she added, failing to hold corporations accountable "has real-life ramifications." Hard to argue with that.
The Alibaba Deal Is a Pattern, Not a One-Off
Here is where it gets worse. CBS News reports that the Alibaba resolution is not some isolated judgment call. It is part of a broader pattern of consumer protection and food safety cases being softened, dropped, or quietly abandoned by senior DOJ leadership under the current administration.
Prosecutors in Washington who traditionally handled criminal Food, Drug and Cosmetic Act cases were reportedly ordered to pull back on investigations for all but the most serious cases. The practical effect of that directive is already showing up in other active investigations.
Take the Philips CPAP case. Since 2022, federal prosecutors in Philadelphia and Washington have been jointly investigating Philips over a recall of some 15 million breathing devices. The sound-reducing foam inside those machines can degrade and cause users to inhale carcinogens. CBS News reports that earlier this spring, prosecutors in Philadelphia learned that their counterparts in DOJ's Criminal Division were no longer permitted to work the Philips case with them. Washington pulled out. Separately, CBS News reports that a criminal investigation into the unlawful importation of adulterated vape products is also no longer receiving support from senior Justice Department leadership.
The Consumer Protection Branch Gets Quietly Gutted
There used to be a unit inside the Justice Department called the Consumer Protection Branch. It handled both criminal and civil enforcement of food and drug safety laws and partnered with U.S. attorneys' offices around the country. CBS News reports that this unit has been restructured in ways that have effectively reduced its capacity to pursue exactly the kinds of corporate cases it was built to handle.
This is how institutional rot works. You do not always announce that you are stopping enforcement. You reassign staff. You change internal guidance. You tell prosecutors in one office they can no longer work with prosecutors in another office. Then a Chinese company that sold fentanyl precursors and pill presses to American consumers walks away with a misdemeanor on its record and its executives sleeping just fine.
The career prosecutors who spent years building these cases are still there, presumably grinding their teeth. Multiple sources spoke to CBS News anonymously because they are still inside the department and the conduct they are describing is happening to them in real time.
The Dingo Take
Let's be precise about what happened here. Prosecutors with evidence of felony violations against a Chinese company that spent eight years helping dangerous drugs reach American consumers asked for a felony resolution. They were overruled. The company admitted to misdemeanors, paid a fine it can absorb, and walked. The Justice Department then called this accountability. The word has lost all meaning.
The Trump administration has spent years performing toughness on China. There are tariffs. There are speeches. There are threats. There is an entire geopolitical posture built around the idea that China is ripping America off and someone is finally going to do something about it. And then a Chinese-owned company facilitates the sale of pill press equipment and counterfeit pharmaceuticals to American customers for nearly a decade, the feds build a felony case, and leadership folds it into a misdemeanor settlement because apparently that is not one of the serious cases. If selling dangerous drugs to Americans through a Chinese platform does not qualify as serious, what exactly does?
The people who will pay the price for this are not the ones in the room when these decisions get made. They are the people who bought something off a sketchy online listing and trusted, somewhere in the back of their minds, that someone in the federal government was watching out for them. That faith was misplaced. The watchdogs got leashed, the paperwork got filed, and somewhere in the DOJ's press office someone typed the word "victory" without their hands shaking even a little.
